Table 1:
Number of participants and families by ascertainment center
| GenoMEL Center | Participants* | Families† | Average number of participants per family‡ | Average number of affected members per family¶ |
|---|---|---|---|---|
| Barcelona, ES | 44 | 25 | 1.8 | 2.1 |
| Bethesda, US | 199 | 46 | 4.3 | 4.8 |
| Cesena, IT | 50 | 24 | 2.1 | 2.1 |
| Copenhagen, DK | 47 | 34 | 1.4 | 2.5 |
| Genoa, IT | 34 | 16 | 2.1 | 2.3 |
| Leeds, GB | 158 | 77 | 2.1 | 2.8 |
| Leiden, NL | 210 | 60 | 3.5 | 4.6 |
| Ljubljana, SI | 9 | 4 | 2.3 | 2.3 |
| Lund, SE | 20 | 7 | 2.9 | 4.4 |
| Montevideo, UY | 8 | 4 | 2.0 | 2.0 |
| Paris, FR | 341 | 176 | 1.9 | 2.5 |
| Philadelphia, US | 78 | 36 | 2.2 | 2.4 |
| Porto Allegre, BR | 9 | 5 | 1.8 | 2.2 |
| Queensland, AU | 96 | 21 | 4.6 | 6.2 |
| Riga, LV | 5 | 5 | 1.0 | 2.6 |
| Santiago, CL | 3 | 2 | 1.5 | 2.0 |
| São Paulo, BR | 13 | 8 | 1.6 | 2.1 |
| Stockholm, SE | 39 | 21 | 1.9 | 2.8 |
| Sydney, AU | 722 | 305 | 2.4 | 3.4 |
| Tel Aviv, IL | 21 | 18 | 1.2 | 2.0 |
| Valencia, ES | 10 | 6 | 1.7 | 2.2 |
| Total | 2116 | 900 | 2.2 | 3.1 |
*
Verification of melanoma was available for >99% of participants by: pathology report (74%), physician letter or clinical document verifying melanoma diagnosis (23%), cancer registry data (2%), or death certificate (<1%). Excludes affected individuals with a diagnosis of non-cutaneous melanoma or who are members of melanoma families by marriage and not ancestry.
†
Family members with a melanoma of the uveal tract or conjunctiva did not contribute to defining a melanoma family.
‡
Includes only participants who contribute to prediction modeling.
¶
Includes family members who may not contribute to prediction modeling because of missing data.